Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase III trial shows vosaroxin improves overall survival in acute myeloid leukaemia

Farhad Ravandi • 6 Dec 2014
ASH 2014
Acute Myeloid Leukemia Cytarabine Vosaroxin

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Farhad Ravandi (The University of Texas MD Anderson Cancer Center, Houston, TX) discusses the phase III double-blind randomized controlled multinational VALOR study, which evaluated vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first-relapsed or refractory acute myeloid leukaemia.

More from Farhad Ravandi

1:23
The value of MRD as a marker for disease eradication in AML
Farhad Ravandi • 8 Dec 2023
1:31
Azacitidine and venetoclax plus gilteritinib in the treatment of FLT3-mutated AML
Farhad Ravandi • 8 Dec 2023
1:29
Poor outcomes of patients with AML who relapse underscores the need for effective initial treatment
Farhad Ravandi • 8 Dec 2023
1:43
Nelarabine, PEG-asparaginase and venetoclax added to HCVAD in T-ALL/T-LBL
Farhad Ravandi • 8 Dec 2023

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals